Cancer peptides of NY-ESO-1/CAG-3

Details Cancer peptides of NY-ESO-1/CAG-3 Cancer peptides of NY-ESO-1/CAG-3

2006-08-01

2006-08-01

Huff, Sheela (Department: 1643)

Chemistry: natural resins or derivatives; peptides or proteins;

Peptides of 3 to 100 amino acid residues

C530S326000, C530S327000, C530S328000, C424S184100, C424S185100

Reexamination Certificate

active

07084239

ABSTRACT:
The present invention discloses the identification, isolation and cloning of a gene encoding a novel cancer antigen NY ESO-1CAG-3 and peptides thereof derived from various open reading frames from the NY ESO-1 gene. The novel cancer antigen and peptides are recognized by cytotoxic T lymphocytes in an HLA restricted manner. The products of the gene are promising candidates for immunotherapeutic strategies for the prevention, treatment and diagnosis of patients with cancer.

REFERENCES:
patent: 5539084 (1996-07-01), Geysen
patent: 5785973 (1998-07-01), Bixler et al.
patent: 5840839 (1998-11-01), Wang et al.
patent: WO 94/03205 (1994-02-01), None
patent: WO 97/29195 (1997-08-01), None
patent: WO 98/14464 (1998-04-01), None
patent: WO 98 32855 (1998-06-01), None
Burgess et al., J of Cell Bio. 111:2129-2138, 1990.
Lazar et al. Molecular and Cellular Biology 8:1247-1252, 1988.
Bowie et al. Science, 247:1306-1310, 1990.
Chen, et al., 1997, Proc. Natl. Acad. Sci. 94:1914.
Reiger et al. Glossary of Genetics and Cytogenetics, Classical and Molecular, 4th Ed., Springer-Verlay, Berlin, 1976.
Riott et al. Immunology, Fourth Edition, 1996, p. 7.9-7.11.
Le Gal et al. Journal of Immunotherapy, 28(3):252-257, May/Jun. 2005.
Khong et al. Journal of Immunotherapy, 27(6):472-477, Nov./Dec. 2004.
Gnjatic et al. Proc. Natl. Acad. Sci. USA, 99(18):11813-11818, 2002.
Burgess et al. Journal of Cell Biology, 111:2129-2138, Nov. 1990.
Lazar et al. Molecular and Cellular Biology, 8(3): 1247-1252, Mar. 1988.
Alberts et al.,Molecular Biology of the Cell, 3rdEd., G-12 (1994).
Branden et al.,Introduction to Protein Structure, 249, (1991).
Estaquier et al.,Eur. J. Immunol., 24(11), 2789-2795 (1994), abstract.
Gill et al.J. Biol. Chem., 242, 3308-3318 (1967).
Chen Y.-T., et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc. Natl. Acad. Sci. USA 94:1914 (1997).
Jager, E., et al. Simultaneous humoral and cellular immu8ne response against cancer-testis antigen NY-ESO-1: definition of human histocompativility leukocyte antigen (HLA)-A2-binding peptide eptiopes. J. Exp. Med. 187:265 (1998).
Parkhurst, et al. Improved induction of melanoma reactive CTL with peptides from the melanoma antigen gp 100 modified at HLA-A0201 binding residues. J. Immunol. 157:2539 (1996).
Wang, R., et al., A breast and melanoma-shared tumor antigen: T cell responses to antigenic peptides translated from different from different open reading frames. J. Immunol. 161:3596 (1998).
Falk et al. Peptide motifs of HLA-A1, -A11, -A31, and -A33 molecules Immunogenetics, vol. 40: 238-241 (1994).
Kawakami, Y et al. Identification of the Immunodominant Peptides of the MART-1 Human Melanoma Antigen Recognized by the Majority of HLA-A2-restricted Tumor Infiltrating lymphocytes. J. Exp. Med., vol. 180: 347 (1994).
Wang, R-F et al. Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes. J. Exp. Med., vol. 181, 799-804 (1995).
Rammensee, H.G. et al. MHC ligand and peptide motifs: first listing, Immunogenetics, vol. 41: 178 (1995).
Wang, R-F, et al. Utilization of an Alternative Open Reading Frame of a Normal Gene in Generating a Novel Human Cancer Antigen, J. Exp. Med. vol. 183: 1131 (1996).
Wang and Rosenberg, Human tumor antigens recognized by T lymphocytes: implications for cancer therapy, J. Leukocyte Biology, vol. 60: 296 (1996).
Wang, R-F et al., Identification of TRP-2 as a Human Tumor Antigen Recognized by cytotoxic T lymphocytes. J. Exp. Med., vol. 184: 2203 (1996).
Kawakami Y et al. Identification of tumor-regression antigens in melanoma. 1. Important Advances in Oncology, 1996, eds. V. DeVita, S. Hellman, S.A. Rosenberg, Lippincott —Raven Publishers, Philadelphia, pp. 3-21.

Affiliated with

Also associated with

Rating

Cancer peptides of NY-ESO-1/CAG-3 does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Cancer peptides of NY-ESO-1/CAG-3, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cancer peptides of NY-ESO-1/CAG-3 will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3634444